The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...